Msd Sub Merck Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MSD SUB MERCK, and what generic alternatives to MSD SUB MERCK drugs are available?
MSD SUB MERCK has thirteen approved drugs.
There are twenty-eight US patents protecting MSD SUB MERCK drugs.
There are six hundred and seventeen patent family members on MSD SUB MERCK drugs in sixty-one countries and one hundred and eighty-one supplementary protection certificates in nineteen countries.
Summary for Msd Sub Merck
| International Patents: | 617 |
| US Patents: | 28 |
| Tradenames: | 12 |
| Ingredients: | 11 |
| NDAs: | 13 |
Drugs and US Patents for Msd Sub Merck
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Msd Sub Merck | SEGLUROMET | ertugliflozin; metformin hydrochloride | TABLET;ORAL | 209806-004 | Dec 19, 2017 | RX | Yes | Yes | 9,308,204 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Msd Sub Merck | ISENTRESS | raltegravir potassium | TABLET;ORAL | 022145-001 | Oct 12, 2007 | RX | Yes | Yes | 7,754,731*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Msd Sub Merck | JANUMET | metformin hydrochloride; sitagliptin phosphate | TABLET;ORAL | 022044-002 | Mar 30, 2007 | RX | Yes | Yes | 6,699,871*PED | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Msd Sub Merck | INVANZ | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 021337-001 | Nov 21, 2001 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Msd Sub Merck | BRIDION | sugammadex sodium | SOLUTION;INTRAVENOUS | 022225-001 | Dec 15, 2015 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Msd Sub Merck | BRIDION | sugammadex sodium | SOLUTION;INTRAVENOUS | 022225-002 | Dec 15, 2015 | AP | RX | Yes | No | RE44733 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |
| Msd Sub Merck | JANUMET | metformin hydrochloride; sitagliptin phosphate | TABLET;ORAL | 022044-002 | Mar 30, 2007 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Msd Sub Merck
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Msd Sub Merck | INVANZ | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 021337-001 | Nov 21, 2001 | 7,342,005*PED | ⤷ Try a Trial |
| Msd Sub Merck | BRIDION | sugammadex sodium | SOLUTION;INTRAVENOUS | 022225-002 | Dec 15, 2015 | 7,265,009 | ⤷ Try a Trial |
| Msd Sub Merck | ISENTRESS | raltegravir potassium | POWDER;ORAL | 205786-001 | Dec 20, 2013 | 7,435,734*PED | ⤷ Try a Trial |
| Msd Sub Merck | INTEGRILIN | eptifibatide | INJECTABLE;INJECTION | 020718-002 | May 18, 1998 | 5,686,570 | ⤷ Try a Trial |
| Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | 8,101,663 | ⤷ Try a Trial |
| Msd Sub Merck | TRUSOPT | dorzolamide hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 020408-001 | Dec 9, 1994 | 4,797,413*PED | ⤷ Try a Trial |
| Msd Sub Merck | BRIDION | sugammadex sodium | SOLUTION;INTRAVENOUS | 022225-001 | Dec 15, 2015 | 6,949,527 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MSD SUB MERCK drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 2 mg/mL, 100 mL vial | ➤ Subscribe | 2008-12-18 |
| ➤ Subscribe | Injection | 1 g/vial | ➤ Subscribe | 2013-06-20 |
| ➤ Subscribe | Ophthalmic Solution | 2% | ➤ Subscribe | 2005-10-11 |
| ➤ Subscribe | Injection | 2 mg/mL, 10 mL vial | ➤ Subscribe | 2008-09-30 |
| ➤ Subscribe | Injection | 0.75 mg/mL, 100 mL vial | ➤ Subscribe | 2009-06-05 |
| ➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2011-10-12 |
| ➤ Subscribe | Tablets | 50 mg/500 mg and 50 mg/1000 mg | ➤ Subscribe | 2010-10-18 |
International Patents for Msd Sub Merck Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 5675071 | ⤷ Try a Trial |
| Spain | 2259713 | ⤷ Try a Trial |
| Japan | 2005525369 | ⤷ Try a Trial |
| Malaysia | 169311 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2007078726 | ⤷ Try a Trial |
| Australia | 2006333151 | ⤷ Try a Trial |
| Denmark | 1819700 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Msd Sub Merck Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2334687 | C20180023 00266 | Estonia | ⤷ Try a Trial | PRODUCT NAME: ERTUGLIFLOSIIN;REG NO/DATE: EU/1/18/1267 23.03.2018 |
| 1259550 | CA 2009 00002 | Denmark | ⤷ Try a Trial | PRODUCT NAME: SUGAMMADEX ELLER FARMACEUTISK AKTIVE SALTE ELLER ESTERE DERAF, HERUNDER SUGAMMADEXNATRIUM |
| 2310095 | C20160051 00215 | Estonia | ⤷ Try a Trial | PRODUCT NAME: GRASOPREVIIR;REG NO/DATE: EU/1/16/1119 26.07.2016 |
| 1441735 | 30/2008 | Austria | ⤷ Try a Trial | PRODUCT NAME: RALTEGRAVIR ODER DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, INSBESONDERE DAS KALIUMSALZ; REGISTRATION NO/DATE: EU/1/07/436 (MITTEILUNG) 20071220 |
| 1412357 | C200700039 | Spain | ⤷ Try a Trial | PRODUCT NAME: SITAGLIPTINA; NATIONAL AUTHORISATION NUMBER: EU/1/07/383/001-018; DATE OF AUTHORISATION: 20070321; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/07/383/001-018; DATE OF FIRST AUTHORISATION IN EEA: 20070321 |
| 1412357 | C 2007 091 | Romania | ⤷ Try a Trial | PRODUCT NAME: (3R)-3-AMINO-1-[9-(TRIFLUOROMETIL)-1,4,7,8-TETRAZABICICLO[4.3.0]NONA-6,8-DIEN-4-IL]-4-(2,4,5-TRIFLUOROFENIL)BUTAN-1-ONA - SITAGLIPTIN; NATIONAL AUTHORISATION NUMBER: RO EU/1/07/383/001 - RO EU/1/07/383/018; DATE OF NATIONAL AUTHORISATION: 20070321; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/07/383/001 - EU/1/07/383/018; DATE OF FIRST AUTHORISATION IN EEA: 20070321 |
| 1506211 | 122014000070 | Germany | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, WIE DURCH DAS GRUNDPATENT GESCHUETZT; REGISTRATION NO/DATE: EU/1/13/900 20140116 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
